 |
|
|
| |
A Phase 4 Study to Evaluate the Safety and
Efficacy of Oral B/F/TAF After Discontinuing
Injectable CAB + RPV
|
| |
| |
IDWeek; October 19-22, 2025; Atlanta, GA, USA
Sharon Walmsley1, Moti Ramgopal2, Thomas Martin3, Jason T Hindman4, Hui Liu4, Keith Aizen5, Jason Okulicz4, Samir Gupta6
1University Health Network, Toronto, ON, Canada; 2Midway Immunology Research Center, Fort Pierce, FL, USA; 3Antiviral Research Center, University of California San Diego, San Diego, CA, USA; 4Gilead Sciences, Inc., Foster City, CA, USA; 5Gilead Sciences, Inc., Cambridge, UK; 6Indiana University School of Medicine, Indianapolis, IN, USA
|
| |
|
|
|
|
|
